Ophthalmology in China
Previous Articles Next Articles
ZHOU Zhe, GAO Yu, SUN Yan, JING Ming, HU Jia-l
Received:
Online:
Published:
Contact:
Abstract:
Objective To determine whether smoking increases adipogenesis of the orbital fatty tissue in patients with thyriod associated ophthalmopathy(TAO). Design Retrospective case series. Participants 40 patients (21 smokers, 8 ex-smokers, 5 passive smokers and 6 nonsmokers) were enrolled. Methods The expression levels of CCAAT/enhancer binging protein(C/EBP) and peroxisome proliferciter-activated receptor γ(PPARγ) of orbital fatty tissue were measured using real-time PCR. Main Outcome Measures C/EBP and PPARγ mRNA expressions. Results Orbital C/EBP and PPARγ mRNA expressions significantly increased in patients with history of smoking (C/EBP: smoker 12.04±4.26 vs non-smoker 2.32±0.92; PPARγ: smoker 4.82±1.41 vs non-smoker 1.37±0.25) (P<0.001), and their expression of ex-smokers and passive smokers were higher than nonsmokers (C/EBP: 4.29±1.26, 5.76±1.03; PPARγ: 2.91±1.23, 3.22±0.50; all P<0.05). Additionally, we found that the expressions of C/EBP (14.28±3.61) and PPARγ mRNA (5.65±1.02) in orbital adipose tissues from TAO patients with higher smoking index(≥100 cigarettes/day years) increased compared with those with lower smoking index(<100 cigarettes/day years)( C/EBP 8.42±2.30;PPARγ 3.48±0.74)(P<0.01). Conclusion Our study suggests that smoking at presentation for TAO increases the levels of C/EBP and PPARγ. (Ophthalmol CHN, 2016, 25: 334-338)
Key words: smoking, thyriod-associated ophthalmopathy, CCAAT/enhancer binging protein(C/EBP), peroxisome proliferciter-activated receptor γ(PPARγ)
ZHOU Zhe, GAO Yu, SUN Yan, JING Ming, HU Jia-li. Smoking increases adipogenesis of orbital fatty tissue in patients with thyriod-associated ophthalmopathy[J]. Ophthalmology in China, doi: 10.13281/j.cnki.issn.1004-4469.2016.05.012.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.j-bio.net/yk/EN/10.13281/j.cnki.issn.1004-4469.2016.05.012
http://www.j-bio.net/yk/EN/Y2016/V25/I5/334